Type 2 Diabetes - Pipeline Review, H1 2018

  • ID: 4564093
  • Drug Pipelines
  • 1109 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Celon Pharma SA
  • Genmedica Therapeutics SL
  • LG Chem Ltd
  • Peptron Inc
  • Sprint Bioscience AB
  • MORE
Type 2 Diabetes - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Report Highlights:

This latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type2 diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Celon Pharma SA
  • Genmedica Therapeutics SL
  • LG Chem Ltd
  • Peptron Inc
  • Sprint Bioscience AB
  • MORE
Introduction

Type2 diabetes - Overview

Type2 diabetes - Therapeutics Development

Type2 diabetes - Therapeutics Assessment

Type2 diabetes - Companies Involved in Therapeutics Development

Type2 diabetes - Drug Profiles

Type2 diabetes - Dormant Projects

Type2 diabetes - Discontinued Products

Type2 diabetes - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Type2 diabetes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Type2 diabetes - Pipeline by Adocia SAS, H1 2018

Type2 diabetes - Pipeline by Aegis Therapeutics LLC, H1 2018

Type2 diabetes - Pipeline by AFFiRiS AG, H1 2018

Type2 diabetes - Pipeline by Akcea Therapeutics Inc, H1 2018

Type2 diabetes - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Type2 diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Type2 diabetes - Pipeline by Amgen Inc, H1 2018

Type2 diabetes - Pipeline by Aphios Corp, H1 2018

Type2 diabetes - Pipeline by Arecor Ltd, H1 2018

Type2 diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2018

Type2 diabetes - Pipeline by AstraZeneca Plc, H1 2018

Type2 diabetes - Pipeline by AusBio Ltd, H1 2018

Type2 diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2018

Type2 diabetes - Pipeline by Bayer AG, H1 2018

Type2 diabetes - Pipeline by Betagenon AB, H1 2018

Type2 diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018

Type2 diabetes - Pipeline by Biocon Ltd, H1 2018

Type2 diabetes - Pipeline by BioLingus AG, H1 2018

Type2 diabetes - Pipeline by BioRestorative Therapies Inc, H1 2018

Type2 diabetes - Pipeline by Biozeus, H1 2018

Type2 diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018

Type2 diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Type2 diabetes - Pipeline by Boston Therapeutics Inc, H1 2018

Type2 diabetes - Pipeline by Braasch Biotech LLC, H1 2018

Type2 diabetes - Pipeline by Bristol-Myers Squibb Co, H1 2018

Type2 diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2018

Type2 diabetes - Pipeline by Cadila Healthcare Ltd, H1 2018

Type2 diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018

Type2 diabetes - Pipeline by Caelus Health, H1 2018

Type2 diabetes - Pipeline by Cardax Inc, H1 2018

Type2 diabetes - Pipeline by Carmot Therapeutics Inc, H1 2018

Type2 diabetes - Pipeline by Cellix Bio Pvt Ltd, H1 2018

Type2 diabetes - Pipeline by Celon Pharma SA, H1 2018

Type2 diabetes - Pipeline by Center Laboratories Inc, H1 2018

Type2 diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2018

Type2 diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Type2 diabetes - Pipeline by Cinnagen Co, H1 2018

Type2 diabetes - Pipeline by CJ HealthCare Corp, H1 2018

Type2 diabetes - Pipeline by CohBar Inc, H1 2018

Type2 diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2018

Type2 diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2018

Type2 diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Type2 diabetes - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Type2 diabetes - Pipeline by Dance Biopharm Inc, H1 2018

Type2 diabetes - Pipeline by Delpor Inc, H1 2018

Type2 diabetes - Pipeline by Diabetology (Products) Ltd, H1 2018

Type2 diabetes - Pipeline by Diamyd Medical AB, H1 2018

Type2 diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2018

Type2 diabetes - Pipeline by DiscoveryBiomed Inc, H1 2018

Type2 diabetes - Pipeline by DNJ Pharma Inc, H1 2018

Type2 diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Type2 diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2018

Type2 diabetes - Pipeline by Eli Lilly and Co, H1 2018

Type2 diabetes - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018

Type2 diabetes - Pipeline by Energenesis Biomedical Co Ltd, H1 2018

Type2 diabetes - Pipeline by Enteris BioPharma Inc, H1 2018

Type2 diabetes - Pipeline by Enzene Biosciences Ltd, H1 2018

Type2 diabetes - Pipeline by Enzo Biochem Inc, H1 2018

Type2 diabetes - Pipeline by Epichem Pty Ltd, H1 2018

Type2 diabetes - Pipeline by Eternygen GmbH, H1 2018

Type2 diabetes - Pipeline by Evotec AG, H1 2018

List of Figures

Number of Products under Development for Type2 diabetes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adocia SAS
  • Aegis Therapeutics LLC
  • AFFiRiS AG
  • Akcea Therapeutics Inc
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Aphios Corp
  • Arecor Ltd
  • Arena Pharmaceuticals Inc
  • AstraZeneca Plc
  • AusBio Ltd
  • Avadel Pharmaceuticals Plc
  • Bayer AG
  • Betagenon AB
  • Betta Pharmaceuticals Co Ltd
  • Biocon Ltd
  • BioLingus AG
  • BioRestorative Therapies Inc
  • Biozeus
  • Biscayne Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Boston Therapeutics Inc
  • Braasch Biotech LLC
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings PLC
  • Cadila Healthcare Ltd
  • Cadila Pharmaceuticals Ltd
  • Caelus Health
  • Cardax Inc
  • Carmot Therapeutics Inc
  • Cellix Bio Pvt Ltd
  • Celon Pharma SA
  • Center Laboratories Inc
  • Chipscreen Biosciences Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Cinnagen Co
  • CJ HealthCare Corp
  • CohBar Inc
  • Concenter BioPharma Silkim Ltd
  • CymaBay Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Dance Biopharm Inc
  • Delpor Inc
  • Diabetology (Products) Ltd
  • Diamyd Medical AB
  • Diasome Pharmaceuticals Inc
  • DiscoveryBiomed Inc
  • DNJ Pharma Inc
  • Dong-A Socio Holdings Co Ltd
  • Elcelyx Therapeutics Inc
  • Eli Lilly and Co
  • Eloxx Pharmaceuticals Inc
  • Energenesis Biomedical Co Ltd
  • Enteris BioPharma Inc
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • Epichem Pty Ltd
  • Eternygen GmbH
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Generex Biotechnology Corp
  • Genexine Inc
  • Genfit SA
  • Genmedica Therapeutics SL
  • Genovate Biotechnology Co LTD
  • Geropharm LLC
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • Hanmi Pharmaceuticals Co Ltd
  • Heptares Therapeutics Ltd
  • HitGen LTD
  • Hyundai Pharmaceutical Co Ltd
  • Immupharma Plc
  • Immuron Ltd
  • Inflazome Ltd
  • Innovative Targeting Solutions Inc
  • Inspyr Therapeutics Inc
  • InStar Technologies AS
  • Intarcia Therapeutics Inc
  • Intas Pharmaceuticals Ltd
  • Integral Molecular Inc
  • Intercept Pharmaceuticals Inc
  • Intrexon Corp
  • Ionis Pharmaceuticals Inc
  • Japan Tobacco Inc
  • Jeil Pharmaceutical Co Ltd
  • JHL Biotech Inc
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Kadimastem Ltd
  • Kadmon Corp LLC
  • Kissei Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Laboratorios Silanes SA de CV
  • Lead Discovery Center GmbH
  • Leading BioSciences Inc
  • Lexicon Pharmaceuticals Inc
  • LG Chem Ltd
  • LipimetiX Development Inc
  • Longevity Biotech Inc
  • Luye Pharma Group Ltd
  • Magnus Life Ltd
  • MannKind Corp
  • Medesis Pharma SA
  • MedImmune LLC
  • Medlab Clinical Ltd
  • Merck & Co Inc
  • Mesoblast Ltd
  • Metabolic Solutions Development Company LLC
  • Metabolys SAS
  • Metacrine Inc
  • Mitsubishi Chemical Holdings Corp
  • Mitsubishi Tanabe Pharma Corp
  • Naia Ltd
  • Neurimmune Holding AG
  • NGM Biopharmaceuticals Inc
  • Novapeutics LLC
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Novo Nordisk AS
  • Omeros Corp
  • OPKO Biologics Ltd
  • OPKO Health Inc
  • Oramed Pharmaceuticals Inc
  • Original BioMedicals Co Ltd
  • Palatin Technologies Inc
  • Panacea Biotec Ltd
  • Paras Biopharmaceuticals Finland Oy
  • Peptron Inc
  • Pfizer Inc
  • PharmaCyte Biotech Inc
  • PharmaIN Corp
  • Pila Pharma AB
  • Poxel SA
  • Prometheon Pharma LLC
  • ProMetic Life Sciences Inc
  • Prothena Corp Plc
  • Purzer Pharmaceutical Co Ltd
  • Reata Pharmaceuticals Inc
  • reMYND NV
  • Renova Therapeutics Inc
  • Reset Therapeutics Inc
  • Rezolute Inc
  • Saniona AB
  • Sanofi
  • Sanwa Kagaku Kenkyusho Co Ltd
  • SATT Conectus Alsace SAS
  • SBI Pharmaceuticals Co Ltd
  • ScandiCure AB
  • Seres Therapeutics Inc
  • Serodus ASA
  • Serometrix LLC
  • Shenzhen HighTide Biopharmaceutical Ltd
  • Shionogi & Co Ltd
  • Sirona Biochem Corp
  • SJT Molecular Research SL
  • SK Chemicals Co Ltd
  • Sprint Bioscience AB
  • Sumitomo Dainippon Pharma Co Ltd
  • Suzuken Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Teijin Pharma Ltd
  • The Medicines Company
  • Theracos Inc
  • Thermalin Diabetes LLC
  • Tiziana Life Sciences Plc
  • Toray Industries Inc
  • Torrent Pharmaceuticals Ltd
  • Transgene Biotek Ltd
  • TTY Biopharm Company Ltd
  • Twoxar Inc
  • Uni-Bio Science Group Ltd
  • ViaCyte Inc
  • Vichem Chemie Research Ltd
  • Vicore Pharma AB
  • Viking Therapeutics Inc
  • Vivus Inc
  • vTv Therapeutics Inc
  • Vybion Inc
  • XBiotech Inc
  • XERIS Pharmaceuticals Inc
  • XL-protein GmbH
  • XOMA Corp
  • XuanZhu Pharma Co Ltd
  • Yabao Pharmaceutical Group Co Ltd
  • Yuhan Corp
  • Zafgen Inc
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll